Report
Dave Nicoski ...
  • Ross LaDuke
EUR 44.79 For Business Accounts Only

Vermilion ETF Pathfinder: Actionable ETF research & Ideas

Upgrading Real Estate, Staples, and Health Care

The S&P 500 (SPX) is back to test YTD highs and important resistance in the 5670-5783 range. This is an important target/resistance area we have discussed for over a month; using the 2007 SPX topping analog which has tracked the current market almost perfectly, it would suggest a 2% or less move above the prior all-time high set in July at 5670 before topping, which is where we get the 5783 number. As long as the SPX does not have a weekly close above 5783 we continue to recommend reducing risk and shifting to defensives, and this is the ideal time to do so. We remain neutral on the SPX, preferring to sell near 5783 resistance and buy near 5100-5200 support until there is a break in either direction.

Upgrading Real Estate, Staples, and Health Care to Overweight. We are upgrading Real Estate (XLRE), Staples (XLP), and Health Care (XLV) to overweight with RS recently making higher highs -- add exposure. Bottoming RS for these defensive Se
Underlyings
AUXLY CANNABIS GROUP INC

Auxly Cannabis Group is engaged in the merchant banking business and operates in a single operating segment within Canada. It enables the private companies in which it invests (the "Investee Companies") the ability to issue debt instruments that are eligible for registered plans as defined in the Income Tax Act (Canada). Co. earns fees from the Investee Companies which are independently managed and operated by their respective management companies. Although Co. owns all or a majority of the voting rights in these Investee Companies, it does not have the power to govern the decisions or policies of the Investee Companies.

iShares Core Canadian Long Ter

REAL ESTATE SPDR

Select Sector SPDR-Consumer Staples

Select Sector SPDR-Energy

Select Sector SPDR-Health Care

Select Sector SPDR-Utilities

The Communication Services Select Sector SPDR Fund

Provider
Vermilion Research
Vermilion Research

Vermilion Research delivers timely, actionable, and unique research inputs to professional investors. Our research strategists highlight securities which we believe are at major inflection points, based on our various proprietary technical indicators, and offer asymmetric risk/return profiles. We believe our research methodology, which is not limited by industry sector or market capitalization, enables us to deliver superior investment recommendations.

Our process begins by organizing all actively traded stocks into coherent sectors, then into logical industry groups. We then apply our proprietary relative strength tools to identify developing price trends. Once attractive trends are identified within a selected sectors or groups, we screen for individual stocks which we believe offer the best risk/reward profile. Vermilion offers U.S. and global equity market research products. Vermilion’s research team, which has received numerous awards and accolades, has a combined 70 year of experience in the analysis of investment securities.

Analysts
Dave Nicoski

Ross LaDuke

Other Reports on these Companies
Other Reports from Vermilion Research

ResearchPool Subscriptions

Get the most out of your insights

Get in touch